Welcome to LookChem.com Sign In|Join Free

CAS

  • or

1260251-31-7

Post Buying Request

1260251-31-7 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • Birinapant;TL32711;Propanamide,N,N'-[(6,6'-difluoro[2,2'-bi-1H-indole]-3,3'-diyl)bis[methylene[(2R,4S)-4-hydroxy-2,1-pyrrolidinediyl][(1S)-1-ethyl-2-oxo-2,1-ethanediyl]]]bis[2-(methylamino)-,(2S,2'S)-

    Cas No: 1260251-31-7

  • No Data

  • 1 Milligram

  • 5

  • Xiamen Jenny Chemical Technology Co., Ltd.
  • Contact Supplier

1260251-31-7 Usage

Description

Birinapant is a bivalent mimetic of the Diablo homolog known as second mitochondria-derived activator of caspase (Smac). It is an antagonist of cellular inhibitor of apoptosis 1 (cIAP1, or BIRC2), cIAP2 (BIRC3), and XIAP (BIRC4), binding each at nanomolar concentrations. Birinapant causes rapid cIAP1 degradation, caspase activation, PARP cleavage, and NF-κB activation in breast cancer cells. It shows in vivo antitumor activity, inducing apoptosis in several types of cancer xenografts in mice.

Uses

Birinapant is a bivalent SMAC mimetic compound antagonist of TRAF2 associated cIAP1 and cIAP2.

Enzyme inhibitor

This rotationally symmetric SMAC mimetic antagonist and anticancer agent (FW = 806.94 g/mol; CAS 1260251-31-7) targets cellular Inhibitor of Apoptosis Protein (or cIAP1; Kd of <1 nM), arguably the most potent mammalian caspase inhibitor, showing single-agent efficacy due to its panIAP antagonism and causing rapid cIAP1 degradation, caspase activation, PARP cleavage, and NF-κB activation. When administered in combination with TNF-α, Birinapant is effective against a melanoma cell line with acquired resistance to BRAF inhibitors

Check Digit Verification of cas no

The CAS Registry Mumber 1260251-31-7 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,6,0,2,5 and 1 respectively; the second part has 2 digits, 3 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 1260251-31:
(9*1)+(8*2)+(7*6)+(6*0)+(5*2)+(4*5)+(3*1)+(2*3)+(1*1)=107
107 % 10 = 7
So 1260251-31-7 is a valid CAS Registry Number.

1260251-31-7SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 17, 2017

Revision Date: Aug 17, 2017

1.Identification

1.1 GHS Product identifier

Product name (2S)-N-[(2S)-1-[(2R,4S)-2-[[6-fluoro-2-[6-fluoro-3-[[(2R,4S)-4-hydroxy-1-[(2S)-2-[[(2S)-2-(methylamino)propanoyl]amino]butanoyl]pyrrolidin-2-yl]methyl]-1H-indol-2-yl]-1H-indol-3-yl]methyl]-4-hydroxypyrrolidin-1-yl]-1-oxobutan-2-yl]-2-(methylamino)propanam

1.2 Other means of identification

Product number -
Other names N-{(1S)-[(2R)-(6,6'-difluoro-3'-{(4S)-hydroxy-1-[(2S)-[(2S)-methylaminopropionylamino]butyryl]pyrrolidin-(2R)-2-ylmethyl}-1H,1 'H-[2,2']biindolyl-3-ylmethyl)-(4S)-hydroxypyrrolidine-1-carbonyl]propyl}-(2S)-methylaminopropionamide

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:1260251-31-7 SDS

1260251-31-7Upstream product

1260251-31-7Downstream Products

1260251-31-7Relevant articles and documents

Process Development and Synthesis of Birinapant: Large Scale Preparation and Acid-Mediated Dimerization of the Key Indole Intermediate

Deng, Yijun,Xie, Qiuzhe,LaPorte, Matthew G.,Chasnoff, Anna T. A.,Mortensen, Mark A.,Patra, Debasis,Putrelo, Seth A.,Antonovich, Robert S.,Cao, Hong,Yan, Jun,Cooper, Arthur J.,Rippin, Susan R.,Alexander, Matthew D.,Kumar, Pavan Tirunahari,Hendi, Mukta S.,Lee, Yu-Hua,Haimowitz, Thomas,Condon, Stephen M.

, p. 242 - 252 (2016/03/04)

Birinapant/TL32711 (1) is a novel bivalent antagonist of the inhibitor of apoptosis (IAP) family of proteins which is currently in clinical development for the treatment of cancer and hepatitis B virus (HBV) infection. In this report, we present a detaile

SMAC Mimetic

-

Page/Page column 15, (2011/01/12)

A SMAC mimetic and pharmaceutical compositions thereof and methods of use.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 1260251-31-7